Takeda has announced a global collaboration and licence agreement with Halozyme to continue advancing vedolizumab with the ...

A combination of the herbal extracts curcumin and Qing Dai can induce remission in a significant proportion of patients with active ulcerative colitis (UC), according to the results of a phase 2 ...

The FDA has approved Xeljanz XR (tofacitinib extended-release; Pfizer) for the treatment of adult patients with moderately to severely active ulcerative colitis. The Food and Drug Administration (FDA) ...

The FDA expanded the indications for guselkumab (Tremfya) to include adults with moderately to severely active ulcerative colitis, Johnson & Johnson announced on Wednesday. Approval of the dual-acting ...

Learn about the potential benefits of the Mediterranean diet for managing ulcerative colitis, including lower inflammation and improved gut health, with expert tips.

October 14, 2009 — Infliximab treatment is linked to lower colectomy rates in patients with moderate to severe active ulcerative colitis, according to the results of a prespecified analysis from 2 ...

Patients with active ulcerative colitis may be able to reduce symptoms and achieve remission by taking a plant-based treatment combining the herbal compounds curcumin and qingdai, preliminary results ...

Adults with moderately to severely active ulcerative colitis (UC) have a new treatment option with the U.S. Food and Drug Administration’s (FDA) recent approval of the oral medication etrasimod ...

The American College of Gastroenterology has released updated guidelines on the diagnosis and management of patients with mildly and moderately to severely active ulcerative colitis. Perspective from ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved golimumab for the treatment of children with moderately to severely active ulcerative ...

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...

SKYWAY (NCT07148414) is a Phase 2 basket trial of SPY072 (anti-TL1A) in patients with moderate to severely active RA, PsA, or axSpA. Enrollment is on track, and all indications are expected to readout ...